Characterizing a Clinical Trial - Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction

被引：1
|
作者：
Wells, Quinn S. [1 ,2 ]
Farber-Eger, Eric [1 ,2 ]
Lipworth, Loren [2 ,3 ]
Dluzniewski, Paul [4 ]
Dent, Ricardo [4 ]
Umeijiego, John [4 ]
Cohen, Sarah S. [3 ,5 ]
机构：
[1] Vanderbilt Univ, Dept Med, Div Cardiovasc Med, Med Ctr, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Vanderbilt Translat & Clin Cardiovasc Res Ctr VTR, Nashville, TN USA
[3] Vanderbilt Univ, Dept Med, Div Epidemiol, Med Ctr, Nashville, TN 37235 USA
[4] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA
[5] Toxstrategies Inc, Epidstrategies, Cary, NC 27511 USA
来源：
CLINICAL EPIDEMIOLOGY | 2022年 / 14卷
关键词：
heart failure; reduced ejection fraction; real-world evidence; electronic health record; RANDOMIZED INTERVENTION TRIAL; CIBIS-II; MORTALITY; ENALAPRIL; SURVIVAL; METOPROLOL; MORBIDITY; OUTCOMES;
D O I：
10.2147/CLEP.S341919
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
li li li Conclusion: Approximately 40% of RW HFrEF patients met criteria for the GALACTICHF trial. While findings of ongoing clinical trials may be directly generalizable to this sizable proportion of patients, future trials should examine whether the majority of patients with lower prevalence of comorbidities and rate of HF hospitalization could benefit from emerging HF treatments.
引用
收藏
页码：39 / 49
页数：11
相关论文
共 50 条
  • [21] A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms
    Beygui, Farzin
    Anguita, Manuel
    Tebbe, Ulrich
    Comin-Colet, Josep
    Galinier, Michel
    Bramlage, Peter
    Turgonyi, Eva
    Lins, Katharina
    Imekraz, Lynda
    de Frutos, Trinidad
    Bohm, Michael
    HEART FAILURE REVIEWS, 2015, 20 (05) : 545 - 552
  • [22] REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Afonso-Silva, M.
    Laires, P. A.
    VALUE IN HEALTH, 2019, 22 : S545 - S545
  • [23] Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
    Ganesananthan, Sashiananthan
    Shah, Nisar
    Shah, Parin
    Elsayed, Hossam
    Phillips, Julie
    Parkes, Ann
    Morgan, Angharad
    Yousef, Zaheer
    OPEN HEART, 2020, 7 (02):
  • [24] Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction
    McCullough, Peter A.
    Mehta, Hirsch S.
    Barker, Colin M.
    Van Houten, Joanna
    Mollenkopf, Sarah
    Gunnarsson, Candace
    Ryan, Michael
    Cork, David P.
    CLINICAL CARDIOLOGY, 2021, 44 (09) : 1192 - 1198
  • [25] New foundational therapy in heart failure with reduced ejection fraction: a real-world experience and the need for changing guidelines
    Pedro Alves Da Silva, P.
    Agostinho, J. R.
    Rodrigues, T.
    Brito, J.
    Couto-Pereira, S.
    Cunha, N.
    Silverio-Antonio, P.
    Valente-Silva, B.
    Rigueira, J.
    Silva, D.
    Lousada, N.
    Pinto, F. J.
    Brito, D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 137 - 137
  • [26] A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms
    Farzin Beygui
    Manuel Anguita
    Ulrich Tebbe
    Josep Comin-Colet
    Michel Galinier
    Peter Bramlage
    Eva Turgonyi
    Katharina Lins
    Lynda Imekraz
    Trinidad de Frutos
    Michael Böhm
    Heart Failure Reviews, 2015, 20 : 545 - 552
  • [27] Real world experience of sacubitril and valsartan in patients with heart failure with reduced ejection fraction
    Ganesananthan, S.
    Shah, N.
    Shah, P.
    Phillips, J.
    Elsayed, H.
    Yousef, Z.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 222 - 222
  • [28] Baseline characteristics and alterations after initiation of therapy with SGLT2i in a real-world heart failure with reduced ejection fraction population
    Stavrati, A.
    Polymeropoulos, K.
    Ioannidis, P.
    Kleitsioti, P.
    Lazaridis, P.
    Zarifis, J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 163 - 163
  • [29] Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan
    Hsiao, Fu-Chih
    Wang, Chun-Li
    Chang, Po-Cheng
    Lu, Yu-Ying
    Huang, Chien-Ying
    Chu, Pao-Hsien
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (02) : 152 - 157
  • [30] Characteristics of asymptomatic heart failure patients with reduced ejection fraction in a large US-based real-world cohort
    Bryant, Allison
    Brecht, Tom
    Behling, Mike
    Starzyk, Kathryn
    Curhan, Gary
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 162 - 163
12345